The immune system and postmenopausal osteoporosis

References

• Acconcia F, Kumar R. (2006). Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett, 238, 1–14
   PubMed Web of Science ®Google Scholar
• Adamopoulos IE, Tessmer M, Chao CC, et al. (2011). IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass. J Immunol, 187, 951–9
   Google Scholar
• Adamski J, Ma Z, Nozell S, Benveniste EN. (2004). 17beta-Estradiol inhibits class II major histocompatibility complex (MHC) expression: influence on histone modifications and cbp recruitment to the class II MHC promoter. Mol Endocrinol, 18, 1963–74
   PubMedGoogle Scholar
• Anginot A, Dacquin R, Mazzorana M, Jurdic P. (2007). Lymphocytes and the Dap12 adaptor are key regulators of osteoclast activation associated with gonadal failure. PLoS One, 2, e585
   Google Scholar
• Ascenzi P, Bocedi A, Marino M. (2006). Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol Aspects Med, 27, 299–402
   PubMedGoogle Scholar
• Bedi B, Li JY, Grassi F, et al. (2010). Inhibition of antigen presentation and T cell costimulation blocks PTH-induced bone loss. Ann NY Acad Sci, 1192, 215–21
   Google Scholar
• Binder NB, Puchner A, Niederreiter B, et al. (2013). Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis. Arthritis Rheum, 65, 608–17
   PubMedGoogle Scholar
• Cenci S, Toraldo G, Weitzmann MN, et al. (2003). Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci USA, 100, 10405–10
   PubMed Web of Science ®Google Scholar
• Cenci S, Weitzmann MN, Roggia C, et al. (2000). Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest, 106, 1229–37
   PubMed Web of Science ®Google Scholar
• Charatcharoenwitthaya N, Khosla S, Atkinson EJ, et al. (2007). Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women. J Bone Miner Res, 22, 724–9
   PubMed Web of Science ®Google Scholar
• Chen L, Wei XQ, Evans B, et al. (2008). IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-kappaB (RANK) expression in myeloid precursor cells. Eur J Immunol, 38, 2845–54
   PubMed Web of Science ®Google Scholar
• Colucci S, Brunetti G, Rizzi R, et al. (2004). T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood, 104, 3722–30
   PubMed Web of Science ®Google Scholar
• D’Amelio P, Cristofaro MA, Grimaldi A, et al. (2010a). The role of circulating bone cell precursors in fracture healing. Calcif Tissue Int, 86, 463–9
   Google Scholar
• D'Amelio P, Grimaldi A, Cristofaro MA, et al. (2010b). Alendronate reduces osteoclast precursors in osteoporosis. Osteoporos Int, 21, 1741–50
   Google Scholar
• D’Amelio P, Grimaldi A, Di Bella S, et al. (2008a). Estrogen deficiency increases osteoclastogenesis upregulating T cells activity: a key mechanism in osteoporosis. Bone, 43, 92–100
   PubMed Web of Science ®Google Scholar
• D’Amelio P, Grimaldi A, Di Bella S, et al. (2008b). Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. JBMR, 23, 373–9
   Google Scholar
• D’Amelio P, Roato I, D’Amico L, et al. (2011). Bone and bone marrow pro-osteoclastogenic cytokines are up-regulated in osteoporosis fragility fractures. Osteoporosis Inter, 22, 2869–77
   PubMedGoogle Scholar
• D'Amico L, Satolli MA, Mecca C, et al. (2013). Bone metastases in gastric cancer follow a RANKL-independent mechanism. Oncol Rep, 29, 1453–8
   Google Scholar
• Das Roy L, Pathangey LB, Tinder TL, et al. (2009). Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis. Breast Cancer Res, 11, R56
   Google Scholar
• d'Elia HF, Carlsten H. (2008). The impact of hormone replacement therapy on humoral and cell-mediated immune responses in vivo in post-menopausal women with rheumatoid arthritis. Scand J Immunol, 68, 661–7
   PubMed Web of Science ®Google Scholar
• Diarra D, Stolina M, Polzer K, et al. (2007). Dickkopf-1 is a master regulator of joint remodeling. Nat Med, 13, 156–63
   PubMed Web of Science ®Google Scholar
• Eghbali-Fatourechi G, Khosla S, Sanyal A, et al. (2003). Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest, 111, 1221–30
   PubMed Web of Science ®Google Scholar
• Gao Y, Grassi F, Ryan M R, et al. (2007). IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest, 117, 122–32
   PubMed Web of Science ®Google Scholar
• Gao Y, Wu X, Terauchi M, et al. (2008). T cells potentiate PTH-induced cortical bone loss through CD40L signaling. Cell Metab, 8, 132–45
   PubMed Web of Science ®Google Scholar
• Giuliani N, Colla S, Sala R, et al. (2002). Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood, 100, 4615–21
   PubMed Web of Science ®Google Scholar
• Grcevic D, Lukic IK, Kovacic N, et al. (2006). Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos. Clin Exp Immunol, 146, 146–58
   PubMed Web of Science ®Google Scholar
• Grewal IS, Flavell RA. (1996). The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev, 153, 85–106
   PubMed Web of Science ®Google Scholar
• Han X, Lin X, Kawai T, et al. (2013). Porphyromonas gingivalis infection-associated periodontal bone resorption is receptor activator of nuclear factor-kappaB ligand (RANKL)-dependent. Infect Immun, 81, 1502–9
   Web of Science ®Google Scholar
• Han X, Lin X, Seliger AR, et al. (2009). Expression of receptor activator of nuclear factor-kappaB ligand by B cells in response to oral bacteria. Oral Microbiol Immunol, 24, 190–6
   Google Scholar
• Hofbauer LC, Khosla S, Dunstan CR, et al. (2000). The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res, 15, 2–12
   PubMed Web of Science ®Google Scholar
• Hofbauer LC, Kühne CA, Viereck V. (2004). The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact, 4, 268–75
   PubMedGoogle Scholar
• Hotokezaka H, Sakai E, Ohara N, et al. (2007). Molecular analysis of RANKL-independent cell fusion of osteoclast-like cells induced by TNF-alpha, lipopolysaccharide, or peptidoglycan. J Cell Biochem, 101, 122–34
   Google Scholar
• Hu Y, Xiong H, Peng B. 2013. Expression of a cytokine, interleukin-23, in experimental periapical lesions. Int Endod J, doi: 10.1111/iej.12077
   Google Scholar
• Kanematsu M, Sato T, Takai H, et al. (2000). Prostaglandin E-2 induces expression of receptor activator of nuclear factor-B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. J Bone Miner Res, 15, 1321–9
   PubMed Web of Science ®Google Scholar
• Kawano Y, Ueno S, Abe M, et al. (2012). TRAIL produced from multiple myeloma cells is associated with osteolytic markers. Oncol Rep, 27, 39–44
   PubMed Web of Science ®Google Scholar
• Kelly M J, Levin E R. (2001). Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol Metab, 12, 152–6
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim K, Youn BU, et al. (2010). MHC class II transactivator negatively regulates RANKL-mediated osteoclast differentiation by downregulating NFATc1 and OSCAR. Cell Signal, 22, 1341–9
   Google Scholar
• Komschlies KL, Back TT, Gregorio TA, et al. (1994). Effects of rhIL-7 on leukocyte subsets in mice: implications for antitumor activity. Immunol Ser, 61, 95–104
   Google Scholar
• Kong YY, Yoshida H, Sarosi I, et al. (1999). OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 397, 315–23
   PubMed Web of Science ®Google Scholar
• Kumru S, Godekmerdan A, Yilmaz B. (2004). Immune effects of surgical menopause and estrogen replacement therapy in peri-menopausal women. J Reprod Immunol, 63, 31–8
   PubMed Web of Science ®Google Scholar
• Lee SK, Kadono Y, Okada F, et al. (2006). T lymphocyte-deficient mice lose trabecular bone mass with ovariectomy. J Bone Miner Res, 21, 1704–12
   PubMed Web of Science ®Google Scholar
• Levin ER. (2002). Cellular functions of plasma membrane estrogen receptors. Steroids, 67, 471–5
   PubMed Web of Science ®Google Scholar
• Li JY, Tawfeek H, Bedi B, et al. (2011). Ovariectomy disregulates osteoblast and osteoclast formation through the T-cell receptor CD40 ligand. Proc Natl Acad Sci USA, 108, 768–73
   Google Scholar
• Li Y, Li A, Yang X, Weitzmann MN. (2007a). Ovariectomy-induced bone loss occurs independently of B cells. J Cell Biochem, 100, 1370–5
   Google Scholar
• Li Y, Toraldo G, Li A, et al. (2007b). B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood, 109, 3839–48
   PubMed Web of Science ®Google Scholar
• Lubberts E, Koenders MI, van den Berg WB. (2005). The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther, 7, 29–37
   PubMed Web of Science ®Google Scholar
• Mackall CL, Fry TJ, Bare C, et al. (2001). IL-7 increases both thymic-dependent and thymic-independent T-cell regeneration after bone marrow transplantation. Blood, 97, 1491–7
   PubMed Web of Science ®Google Scholar
• Mueller RB, Skapenko A, Grunke M, et al. (2005). Regulation of myeloid cell function and major histocompatibility complex class II expression by tumor necrosis factor. Arthritis Rheum, 52, 451–60
   Google Scholar
• Nilsson S, Makela S, Treuter E, et al. (2001). Mechanisms of estrogen action. Physiol Rev, 81, 1535–65
   PubMed Web of Science ®Google Scholar
• Onal M, Xiong J, Chen X, et al. (2012). Receptor activator of nuclear factor κB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem, 287, 29851–60
   PubMed Web of Science ®Google Scholar
• Oostlander AE, Everts V, Schoenmaker T, et al. (2012). T cell-mediated increased osteoclast formation from peripheral blood as a mechanism for Crohn's disease-associated bone loss. J Cell Biochem, 113, 260–8
   Google Scholar
• Porter VR, Greendale GA, Schocken M, Zhu X, Effros RB. (2001). Immune effects of hormone replacement therapy in post-menopausal women. Exp Gerontol, 36, 311–26
   PubMed Web of Science ®Google Scholar
• Quinn JM, Sims NA, Saleh H, et al. (2008). IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice. J Immunol, 181, 5720–9
   PubMed Web of Science ®Google Scholar
• Rifas L, Weitzmann MN. (2009). A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner. Arthritis Rheum, 60, 3324–35
   Google Scholar
• Roato I, Brunetti G, Gorassini E, et al. (2006). IL-7 up-regulates TNF-alpha-dependent osteoclastogenesis in patients affected by solid tumor. PLoS One, 1, e124
   PubMed Web of Science ®Google Scholar
• Roato I, Caldo D, D'Amico L, et al. (2010). Osteoclastogenesis in peripheral blood mononuclear cell cultures of periprosthetic osteolysis patients and the phenotype of T cells localized in periprosthetic tissues. Biomaterials, 31, 7519–25
   Google Scholar
• Roato I, D’Amelio P, Gorassini E, et al. (2008). Osteoclasts are active in bone forming metastases of prostate cancer patients. PLoS One, 3, e3627
   Google Scholar
• Roato I, Gorassini E, Brunetti G, et al. (2007). IL-7 modulates osteoclastogenesis in patients affected by solid tumors. Ann NY Acad Sci, 1117, 377–84
   PubMedGoogle Scholar
• Roato I, Grano M, Brunetti G, et al. (2005). Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB J, 19, 228–30
   PubMedGoogle Scholar
• Rogers A, Eastell R. (2001). The effect of 17beta-estradiol on production of cytokines in cultures of peripheral blood. Bone, 29, 30–4
   PubMed Web of Science ®Google Scholar
• Roggia C, Gao Y, Cenci S, et al. (2001). Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA, 98, 13960–9665
   PubMed Web of Science ®Google Scholar
• Ryan MR, Shepherd R, Leavey JK, et al. (2005) An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency. Proc Natl Acad Sci USA, 102, 16735–40
   Google Scholar
• Safe S. (2001). Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm, 62, 231–52
   PubMed Web of Science ®Google Scholar
• Smith C L, O'Malley B W. (2004). Coregulator function: A key to understanding tissue specificity of selective receptor modulators. Endocr Rev, 25, 45–71
   PubMed Web of Science ®Google Scholar
• Suda T, Takahashi N, Udagawa N, et al. (1999). Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev, 20, 345–57
   PubMed Web of Science ®Google Scholar
• Takahata M, Maher JR, Juneja SC, et al. (2012). Mechanisms of bone fragility in a mouse model of glucocorticoid-treated rheumatoid arthritis: implications for insufficiency fracture risk. Arthritis Rheum, 64, 3649–59
   Google Scholar
• Toraldo G, Roggia C, Qian WP, et al. (2003). IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci USA, 100, 125–30
   PubMed Web of Science ®Google Scholar
• Tsai MJ, O'Malley BW. (1994). Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem, 63, 451–86
   PubMed Web of Science ®Google Scholar
• Tyagi AM, Srivastava K, Mansoori MN, et al. (2012). Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: A new candidate in the pathogenesis of osteoporosis. PLoS One, 7, e44552
   PubMed Web of Science ®Google Scholar
• Udagawa N, Takahashi N, Jimi E, et al. (1999). Osteoblasts/stromal cells stimulate osteoclast activation through expression of osteoclast differentiation factor/RANKL but not macrophage colony-stimulating factor: receptor activator of NF-kappa B ligand. Bone, 25, 517–23
   PubMed Web of Science ®Google Scholar
• Wei S, Kitaura H, Zhou P, et al. (2005). IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest, 115, 282–90
   PubMed Web of Science ®Google Scholar
• Weitzmann MN, Roggia C, Toraldo G, et al. (2002). Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J Clin Invest, 110, 1643–50
   PubMed Web of Science ®Google Scholar
• Wheater G, Hogan VE, Teng YK, et al. (2011). Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis. Osteoporos Int, 22, 3067–72
   PubMed Web of Science ®Google Scholar
• Wyzga N, Varghese S, Wikel S, et al. (2004). Effects of activated T cells on osteoclastogenesis depend on how they are activated. Bone, 35, 614–20
   Google Scholar
• Xue Y, Jiang L, Cheng Q, et al. (2012). Adipokines in psoriatic arthritis patients: the correlations with osteoclast precursors and bone erosions. PLoS One, 7, e46740
   PubMed Web of Science ®Google Scholar
• Yago T, Nanke Y, Kawamoto M, et al. (2007). IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther, 9, R96
   PubMed Web of Science ®Google Scholar
• Yao Z, Painter SL, Fanslow WC, et al. (1995). Human IL-17: a novel cytokine derived from T cells. J Immunol, 155, 5483–6
   PubMed Web of Science ®Google Scholar
• Yeo L, Toellner KM, Salmon M, et al. (2011). Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis. Ann Rheum Dis, 70, 2022–8
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Ukai T, Ayon Haro ER, et al. (2011). Membrane-bound CD40 ligand on T cells from mice injected with lipopolysaccharide accelerates lipopolysaccharide-induced osteoclastogenesis. J Periodontal Res, 46, 464–74
   Google Scholar
• Yun TJ, Chaudhary PM, Shu GL, et al. (1998). OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol, 161, 6113–21
   PubMed Web of Science ®Google Scholar
• Zheng SX, Vrindts Y, Lopez M, et al. (1997). Increase in cytokine production (IL-1 beta, IL-6, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis. Maturitas, 26, 63–71
   PubMed Web of Science ®Google Scholar